Skip to main navigation menu Skip to main content Skip to site footer
Brazilian Journal of Clinical Medicine and Review

Health Review

Vol. 3 No. 1 (2025): January/December - 2025

The Role of Microglia in Parkinson's Disease and Possible Therapeutic Targets

DOI
https://doi.org/10.52600/2965-0968.bjcmr.2025.3.1.bjcmr11
Submitted
June 12, 2024
Published
2024-07-31

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to significant motor and non-motor symptoms. Recent research highlights the critical role of microglia, the resident immune cells of the central nervous system, in the pathogenesis and progression of PD. Microglia contribute to neuroinflammation through the release of pro-inflammatory cytokines and reactive oxygen species, exacerbating neuronal damage. Moreover, α-synuclein aggregates, a hallmark of PD, activate microglia, further promoting inflammation and neurodegeneration. This review explores the dual role of microglia in PD, encompassing both their neuroprotective functions and their contribution to neuroinflammation. We discuss the molecular mechanisms underlying microglial activation and their interactions with astrocytes, another crucial glial cell type. The review also examines potential therapeutic targets aimed at modulating microglial activity to mitigate neuroinflammation and slow the progression of PD. Current therapeutic strategies predominantly focus on symptomatic relief through dopaminergic medications. However, emerging therapies targeting microglial activation, such as anti-inflammatory drugs, immunomodulators, and novel agents like metabotropic glutamate receptor 5 (mGluR5) modulators, offer promising avenues for disease modification. Understanding the complex interplay between microglia and other cellular components in the PD brain is essential for developing effective treatments that address the underlying pathophysiological mechanisms of the disease.

References

  1. Ding W, Ding LJ, Li FF, Han Y, Mu L. Neurodegeneration and cognition in Parkinson's disease: a review. Eur Rev Med Pharmacol Sci. 2015 Jun;19(12):2275-81. PMID: 26166654.
  2. Miyazaki I, Asanuma M. Neuron-Astrocyte Interactions in Parkinson's Disease. Cells. 2020 Dec 7;9(12):2623. doi: 10.3390/cells9122623. PMID: 33297340; PMCID: PMC7762285.
  3. Sousa NMF, Neri ACM, Brandi IV, Brucki SMD. Impact of cognitive intervention on cognitive symptoms and quality of life in idiopathic Parkinson's disease: a randomized and controlled study. Dement. Neuropsychol. 2021;15(1):51-5
  4. Toledo ARL, Monroy GR, Salazar FE, Lee JY, Jain S, Yadav H, Borlongan CV. Gut-Brain Axis as a Pathological and Therapeutic Target for Neurodegenerative Disorders. Int J Mol Sci. 2022 Jan 21;23(3):1184. doi: 10.3390/ijms23031184. PMID: 35163103; PMCID: PMC8834995.
  5. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020 Feb;36(1):1-12. doi: 10.1016/j.cger.2019.08.002. Epub 2019 Aug 24. PMID: 31733690; PMCID: PMC6905381.
  6. Erkkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):a033118. doi: 10.1101/cshperspect.a033118. PMID: 28716886; PMCID: PMC5880171.
  7. Moustafa SA, Mohamed S, Dawood A, Azar J, Elmorsy E, Rizk NAM, Salama M. Gut brain axis: an insight into microbiota role in Parkinson's disease. Metab Brain Dis. 2021.
  8. Kam TI, Hinkle JT, Dawson TM, Dawson VL. Microglia and astrocyte dysfunction in parkinson's disease. Neurobiol Dis. 2020 Oct;144:105028. doi: 10.1016/j.nbd.2020.105028. Epub 2020 Jul 28. PMID: 32736085; PMCID: PMC7484088.
  9. Frouni I, Kwan C, Belliveau S, Huot P. Cognition and serotonin in Parkinson's disease. Prog Brain Res. 2022;269(1):373-403. doi: 10.1016/bs.pbr.2022.01.013. Epub 2022 Feb 4. PMID: 35248202.
  10. Pajares M, I Rojo A, Manda G, Boscá L, Cuadrado A. Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications. Cells. 2020 Jul 14;9(7):1687. doi: 10.3390/cells9071687. PMID: 32674367; PMCID: PMC7408280.
  11. Kwon OC, Song JJ, Yang Y, Kim SH, Kim JY, Seok MJ, Hwang I, Yu JW, Karmacharya J, Maeng HJ, Kim J, Jho EH, Ko SY, Son H, Chang MY, Lee SH. SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models. EMBO Mol Med. 2021 Apr 9;13(4):e13076. doi: 10.15252/emmm.202013076. Epub 2021 Mar 1. PMID: 33646633; PMCID: PMC8033538.
  12. Zhang YN, Fan JK, Gu L, Yang HM, Zhan SQ, Zhang H. Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson's disease. J Neuroinflammation. 2021 Jan 18;18(1):23. doi: 10.1186/s12974-021-02079-1. PMID: 33461598; PMCID: PMC7814625.
  13. Yang L, Mao K, Yu H, Chen J. Neuroinflammatory Responses and Parkinson' Disease: Pathogenic Mechanisms and Therapeutic Targets. J Neuroimmune Pharmacol. 2020 Dec;15(4):830-837. doi: 10.1007/s11481-020-09926-7. Epub 2020 Jun 11. PMID: 32529463
  14. Guo M, Wang J, Zhao Y, Feng Y, Han S, Dong Q, Cui M, Tieu K. Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease. Brain. 2020 May 1;143(5):1476-1497. doi: 10.1093/brain/awaa090. PMID: 32355963; PMCID: PMC7241957.
  15. Aoyama K. Glutathione in the Brain. Int J Mol Sci. 2021 May 9;22(9):5010. doi: 10.3390/ijms22095010. PMID: 34065042; PMCID: PMC8125908.
  16. Sarkar S, Nguyen HM, Malovic E, Luo J, Langley M, Palanisamy BN, Singh N, Manne S, Neal M, Gabrielle M, Abdalla A, Anantharam P, Rokad D, Panicker N, Singh V, Ay M, Charli A, Harischandra D, Jin LW, Jin H, Rangaraju S, Anantharam V, Wulff H, Kanthasamy AG. Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease. J Clin Invest. 2020 Aug 3;130(8):4195-4212. doi: 10.1172/JCI136174. PMID: 32597830; PMCID: PMC7410064.
  17. Krajcovicova L, Klobusiakova P, Rektorova I. Gray Matter Changes in Parkinson's and Alzheimer's Disease and Relation to Cognition. Curr Neurol Neurosci Rep. 2019 Nov 13;19(11):85. doi: 10.1007/s11910-019-1006-z. PMID: 31720859; PMCID: PMC6854046.
  18. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020 Feb;36(1):1-12. doi: 10.1016/j.cger.2019.08.002. Epub 2019 Aug 24. PMID: 31733690; PMCID: PMC6905381.
  19. Belarbi K, Cuvelier E, Bonte MA, Desplanque M, Gressier B, Devos D, Chartier-Harlin MC. Glycosphingolipids and neu-roinflammation in Parkinson's disease. Mol Neurodegener. 2020 Oct 17;15(1):59. doi: 10.1186/s13024-020-00408-1. PMID: 33069254; PMCID: PMC7568394.
  20. Claudino Dos Santos JC, Lima MPP, Brito GAC, Viana GSB. Role of enteric glia and microbiota-gut-brain axis in parkinson disease pathogenesis. Ageing Res Rev. 2022 Nov 29;84:101812. doi: 10.1016/j.arr.2022.101812
  21. Pediaditakis I, Kodella KR, Manatakis DV, Le CY, Hinojosa CD, Tien-Street W, Manolakos ES, Vekrellis K, Hamilton GA, Ewart L, Rubin LL, Karalis K. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. Nat Commun. 2021 Oct 8;12(1):5907. doi: 10.1038/s41467-021-26066-5. PMID: 34625559; PMCID: PMC8501050.
  22. Pawelec P, Ziemka-Nalecz M, Sypecka J, Zalewska T. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders. Cells. 2020 Oct 13;9(10):2277. doi: 10.3390/cells9102277. PMID: 33065974; PMCID: PMC7600611.
  23. Cheng J, Zhang R, Xu Z, Ke Y, Sun R, Yang H, Zhang X, Zhen X, Zheng LT. Early glycolytic reprogramming controls microglial inflammatory activation. J Neuroinflammation. 2021 Jun 9;18(1):129. doi: 10.1186/s12974-021-02187-y. PMID: 34107997; PMCID: PMC8191212.
  24. Huang J, Huang N, Xu S, Luo Y, Li Y, Jin H, Yu C, Shi J, Jin F. Signaling mechanisms underlying inhibition of neuroin-flammation by resveratrol in neurodegenerative diseases. J Nutr Biochem. 2021 Feb;88:108552. doi: 10.1016/j.jnutbio.2020.108552. Epub 2020 Nov 18. PMID: 33220405.
  25. Franco R, Lillo A, Rivas-Santisteban R, Reyes-Resina I, Navarro G. Microglial Adenosine Receptors: From Preconditioning to Modulating the M1/M2 Balance in Activated Cells. Cells. 2021 May 7;10(5):1124. doi: 10.3390/cells10051124. PMID: 34066933; PMCID: PMC8148598.
  26. Stevenson R, Samokhina E, Rossetti I, Morley JW, Buskila Y. Neuromodulation of Glial Function During Neurodegeneration. Front Cell Neurosci. 2020 Aug 21;14:278. doi: 10.3389/fncel.2020.00278. PMID: 32973460; PMCID: PMC7473408.
  27. Mohamed MA, Zeng Z, Gennaro M, Lao-Kaim NP, Myers JFM, Calsolaro V, Femminella GD, Tyacke RJ, Martin-Bastida A, Gunn RN, Nutt DJ, Edison P, Piccini P, Roussakis AA. Astrogliosis in aging and Parkinson's disease dementia: a new clinical study with 11C-BU99008 PET. Brain Commun. 2022 Aug 18;4(5):fcac199. doi: 10.1093/braincomms/fcac199. PMID: 36072646; PMCID: PMC9445175.
  28. Zang X, Chen S, Zhu J, Ma J, Zhai Y. The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases. Front Aging Neurosci. 2022 Apr 25;14:872134. doi: 10.3389/fnagi.2022.872134. PMID: 35547626; PMCID: PMC9082639.
  29. Sindona C, Schepici G, Contestabile V, Bramanti P, Mazzon E. NOX2 Activation in COVID-19: Possible Implications for Neurodegenerative Diseases. Medicina (Kaunas). 2021 Jun 11;57(6):604. doi: 10.3390/medicina57060604. PMID: 34208136; PMCID: PMC8230853.
  30. Chavarría C, Ivagnes R, Souza JM. Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation. Biomolecules. 2022 Apr 30;12(5):655. doi: 10.3390/biom12050655. PMID: 35625583; PMCID: PMC9138387.
  31. Li KL, Huang HY, Ren H, Yang XL. Role of exosomes in the pathogenesis of inflammation in Parkinson's disease. Neural Regen Res. 2022 Sep;17(9):1898-1906. doi: 10.4103/1673-5374.335143. PMID: 35142665; PMCID: PMC8848593.
  32. Li L, Acioglu C, Heary RF, Elkabes S. Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases. Brain Behav Immun. 2021 Jan;91:740-755. doi: 10.1016/j.bbi.2020.10.007. Epub 2020 Oct 8. PMID: 33039660; PMCID: PMC7543714.
  33. Ganguly U, Singh S, Chakrabarti S, Saini AK, Saini RV. Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein. Adv Protein Chem Struct Biol. 2022;129:381-433. doi: 10.1016/bs.apcsb.2021.11.010. Epub 2021 Dec 28. PMID: 35305723.
  34. Forloni G, La Vitola P, Cerovic M, Balducci C. Inflammation and Parkinson's disease pathogenesis: Mechanisms and thera-peutic insight. Prog Mol Biol Transl Sci. 2021;177:175-202. doi: 10.1016/bs.pmbts.2020.11.001. Epub 2020 Dec 15. PMID: 33453941.
  35. Rasheed M, Liang J, Wang C, Deng Y, Chen Z. Epigenetic Regulation of Neuroinflammation in Parkinson's Disease. Int J Mol Sci. 2021 May 7;22(9):4956. doi: 10.3390/ijms22094956. PMID: 34066949; PMCID: PMC8125491.
  36. Landrigan J, Dwyer Z, Beauchamp S, Rodriguez R, Fortin T, Hayley S. Quantum dot conjugated saporin activates microglia and induces selective substantia nigra degeneration. Neurotoxicology. 2020 Jan;76:153-161. doi: 10.1016/j.neuro.2019.11.007. Epub 2019 Nov 15. PMID: 31738977.
  37. Salmina AB, Kapkaeva MR, Vetchinova AS, Illarioshkin SN. Novel Approaches Used to Examine and Control Neurogenesis in Parkinson's Disease. Int J Mol Sci. 2021 Sep 4;22(17):9608. doi: 10.3390/ijms22179608. PMID: 34502516; PMCID: PMC8431772.
  38. Takahashi S, Mashima K. Neuroprotection and Disease Modification by Astrocytes and Microglia in Parkinson Disease. Antioxidants (Basel). 2022 Jan 17;11(1):170. doi: 10.3390/antiox11010170. PMID: 35052674; PMCID: PMC8773262.
  39. Sanchez A, Morales I, Rodriguez-Sabate C, Sole-Sabater M, Rodriguez M. Astrocytes, a Promising Opportunity to Control the Progress of Parkinson's Disease. Biomedicines. 2021 Sep 28;9(10):1341. doi: 10.3390/biomedicines9101341. PMID: 34680458; PMCID: PMC8533570.
  40. MacMahon Copas AN, McComish SF, Fletcher JM, Caldwell MA. The Pathogenesis of Parkinson's Disease: A Complex In-terplay Between Astrocytes, Microglia, and T Lymphocytes? Front Neurol. 2021 May 26;12:666737. doi: 10.3389/fneur.2021.666737. PMID: 34122308; PMCID: PMC8189423.
  41. Lee HG, Wheeler MA, Quintana FJ. Function and therapeutic value of astrocytes in neurological diseases. Nat Rev Drug Discov. 2022 May;21(5):339-358. doi: 10.1038/s41573-022-00390-x. Epub 2022 Feb 16. PMID: 35173313; PMCID: PMC9081171.
  42. Singh D. Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease. J Neuroinflamma-tion. 2022 Aug 17;19(1):206. doi: 10.1186/s12974-022-02565-0. PMID: 35978311; PMCID: PMC9382837.
  43. Rostami J, Mothes T, Kolahdouzan M, Eriksson O, Moslem M, Bergström J, Ingelsson M, O'Callaghan P, Healy LM, Falk A, Erlandsson A. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates. J Neuroinflammation. 2021 Jun 3;18(1):124. doi: 10.1186/s12974-021-02158-3. PMID: 34082772; PMCID: PMC8173980.
  44. Wang H, Liu Y, Zhao J, Guo X, Hu M, Chen Y. Possible inflammatory mechanisms and predictors of Parkinson's disease patients with fatigue (Brief Review). Clin Neurol Neurosurg. 2021 Sep;208:106844. doi: 10.1016/j.clineuro.2021.106844. Epub 2021 Aug 4. PMID: 34388595.
  45. Araújo B, Caridade-Silva R, Soares-Guedes C, Martins-Macedo J, Gomes ED, Monteiro S, Teixeira FG. Neuroinflammation and Parkinson's Disease-From Neurodegeneration to Therapeutic Opportunities. Cells. 2022 Sep 17;11(18):2908. doi: 10.3390/cells11182908. PMID: 36139483; PMCID: PMC9497016. https://pubmed.ncbi.nlm.nih.gov/36139483/
  46. Smajić S, Prada-Medina CA, Landoulsi Z, Ghelfi J, Delcambre S, Dietrich C, Jarazo J, Henck J, Balachandran S, Pachchek S, Morris CM, Antony P, Timmermann B, Sauer S, Pereira SL, Schwamborn JC, May P, Grünewald A, Spielmann M. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain. 2022 Apr 29;145(3):964-978. doi: 10.1093/brain/awab446. PMID: 34919646; PMCID: PMC9050543.
  47. Liu LR, Liu JC, Bao JS, Bai QQ, Wang GQ. Interaction of Microglia and Astrocytes in the Neurovascular Unit. Front Immunol. 2020 Jul 8;11:1024. doi: 10.3389/fimmu.2020.01024. PMID: 32733433; PMCID: PMC7362712.
  48. Olude MA, Mouihate A, Mustapha OA, Farina C, Quintana FJ, Olopade JO. Astrocytes and Microglia in Stress-Induced Neu-roinflammation: The African Perspective. Front Immunol. 2022 May 30;13:795089. doi: 10.3389/fimmu.2022.795089. PMID: 35707531; PMCID: PMC9190229.
  49. Wei X, Cho KS, Thee EF, Jager MJ, Chen DF. Neuroinflammation and microglia in glaucoma: time for a paradigm shift. J Neurosci Res. 2019 Jan;97(1):70-76. doi: 10.1002/jnr.24256. Epub 2018 May 18. Erratum in: J Neurosci Res. 2019 Mar;97(3):374. PMID: 29775216; PMCID: PMC6239948.
  50. Di Benedetto G, Burgaletto C, Bellanca CM, Munafò A, Bernardini R, Cantarella G. Role of Microglia and Astrocytes in Alzheimer's Disease: From Neuroinflammation to Ca2+ Homeostasis Dysregulation. Cells. 2022 Sep 1;11(17):2728. doi: 10.3390/cells11172728. PMID: 36078138; PMCID: PMC9454513.
  51. Cragnolini AB, Lampitella G, Virtuoso A, Viscovo I, Panetsos F, Papa M, Cirillo G. Regional brain susceptibility to neuro-degeneration: what is the role of glial cells? Neural Regen Res. 2020 May;15(5):838-842. doi: 10.4103/1673-5374.268897. PMID: 31719244; PMCID: PMC6990768.
  52. Jang JH, Yeom MJ, Ahn S, Oh JY, Ji S, Kim TH, Park HJ. Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease. Brain Behav Immun. 2020 Oct;89:641-655. doi: 10.1016/j.bbi.2020.08.015. Epub 2020 Aug 19. PMID: 32827699.

Most read articles by the same author(s)

1 2 > >>